Eton Pharmaceuticals (ETON) Net Income towards Common Stockholders (2018 - 2025)

Eton Pharmaceuticals (ETON) has 8 years of Net Income towards Common Stockholders data on file, last reported at $1.7 million in Q4 2025.

• For the quarter ending Q4 2025, Net Income towards Common Stockholders rose 383.61% year-over-year to $1.7 million; the trailing twelve-month figure through Dec 2025 stood at -$4.4 million (down 14.78% YoY), and the FY2025 full-year result was -$4.4 million, down 14.78% from the prior year.
• Net Income towards Common Stockholders grew to $1.7 million in Q4 2025, from -$1.9 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $5.1 million in Q1 2021 to a low of -$6.1 million in Q3 2021.
• A 5-year average of -$891850.0 and a median of -$1.6 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders jumped 392.62% in 2023 and sank 407.34% in 2025, its largest moves.
• Tracing ETON's Net Income towards Common Stockholders over 5 years: stood at $1.0 million in 2021, then jumped by 170.07% to $2.8 million in 2022, then sank by 166.43% to -$1.9 million in 2023, then soared by 67.92% to -$598000.0 in 2024, then surged by 383.61% to $1.7 million in 2025.
• Business Quant data shows ETON's Net Income towards Common Stockholders at $1.7 million in Q4 2025, -$1.9 million in Q3 2025, and -$2.6 million in Q2 2025.